Elena Mishchenko

The Use of Point-of-Care Hemoglobin Measurements in an Elderly Population with Hematological Disorders and Anemia

Ittai Appel, Liat Dizengoff, Nili Stein, Regina Draliuk et autres

il (code pays fourni par la source)

Selinexor Plus Ruxolitinib in Janus Kinase Inhibitor–Naïve Myelofibrosis: Phase III SENTRY Trial

Prithviraj Bose, Haris Ali, Haifa Kathrin Al-Ali, Valentín García‐Gutiérrez et autres

us, de, es, pl, bg, gb, kr, tw, fr, it, ro (code pays fourni par la source)

Assessing the correlation between patient and family reported outcome measures and multiple myeloma clinical parameters

Mouna Ballan‐Haj, Kareem Midlej, Barbara Silverman, Regina Draliuk et autres

il (code pays fourni par la source)

Prioritization of potential pharmacological targets for the development of anti-hepatocarcinoma drugs modulating the extrinsic apoptosis pathway: the reconstruction and analysis of associative gene networks help

П. С. Деменков, A. V. Adamovskaya, Elena Mishchenko, Т. М. Хлебодарова et autres

ru, de (code pays fourni par la source)

Multicenter Retrospective Analysis of Eosinophilic Myeloid Neoplasms

Eoghan Molloy, William Shomali, Maggie J. Cox, Joseph H. Butterfield et autres

ie, us, be, pl, fr, il (code pays fourni par la source)

S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX

John Mascarenhas, Tania Jain, Salman Otoukesh, Aaron T. Gerds et autres

us, it, fr, il, bg, de (code pays fourni par la source)

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi, Haifa Kathrin Al‐Ali et autres

us, it, de, il, pl, sg, hu, es, gb, au, kr, ca, fr, be (code pays fourni par la source)

P-192: Patient reported outcome & family reported outcome and the most correlated clinical measures over one year of follow-Up

Kareem Midlig, Barbara Silverman, Regina Draliuk, Elena Mishchenko et autres

Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis

Animesh Pardanani, Ayalew Tefferi, Tamás Masszi, Elena Mishchenko et autres

us, hu, il, gb, fr, it, lt, sg (code pays fourni par la source)

Management and Outcome of Venous Thrombosis in Patients with Myeloproliferative Neoplasms: Data from the Israeli MPN Working Group

Odit Gutwein, Noa Lavi, Merav Barzilai, Adi Shacham‐Abulafia et autres

il (code pays fourni par la source)

Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate-2 or High-Risk Myelofibrosis (MF): Updated Results from the Randomized, Placebo-Controlled, Phase III JAKARTA Trial

Animesh Pardanani, Ayalew Tefferi, Tamás Masszi, Elena Mishchenko et autres

us, hu, gb, fr, it, lt, sg (code pays fourni par la source)

Association between myelofibrosis and risk of non-hematologic malignancies: a population-based retrospective cohort study

Walid Saliba, Maria Khudyakova, Elena Mishchenko, Shai Cohen et autres

il (code pays fourni par la source)